First Trust Advisors LP Has $222.99 Million Holdings in Cencora, Inc. $COR

First Trust Advisors LP decreased its holdings in Cencora, Inc. (NYSE:COR) by 2.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 713,492 shares of the company’s stock after selling 20,700 shares during the period. First Trust Advisors LP’s holdings in Cencora were worth $222,988,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. United Bank grew its position in shares of Cencora by 4.5% in the 2nd quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after buying an additional 305 shares during the last quarter. Crestwood Advisors Group LLC raised its position in shares of Cencora by 18.9% during the second quarter. Crestwood Advisors Group LLC now owns 1,376 shares of the company’s stock worth $413,000 after acquiring an additional 219 shares during the last quarter. Savant Capital LLC lifted its stake in shares of Cencora by 8.4% in the second quarter. Savant Capital LLC now owns 8,251 shares of the company’s stock worth $2,474,000 after acquiring an additional 639 shares during the period. Vestmark Advisory Solutions Inc. acquired a new position in shares of Cencora in the second quarter worth approximately $4,233,000. Finally, Fox Run Management L.L.C. bought a new stake in Cencora in the second quarter valued at approximately $448,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Down 0.4%

Shares of NYSE COR opened at $357.98 on Friday. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The company has a 50-day moving average price of $354.16 and a 200-day moving average price of $336.45. The stock has a market capitalization of $69.64 billion, a P/E ratio of 43.03, a P/E/G ratio of 1.67 and a beta of 0.68. Cencora, Inc. has a 1 year low of $251.94 and a 1 year high of $377.54.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same quarter in the prior year, the business posted $3.73 EPS. The firm’s revenue was up 5.5% compared to the same quarter last year. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s dividend payout ratio (DPR) is currently 28.85%.

Insider Activity at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 15,220 shares of company stock valued at $5,282,867 over the last 90 days. Insiders own 0.38% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Bank of America decreased their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research report on Monday, January 5th. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. TD Cowen increased their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Finally, Wells Fargo & Company upped their price target on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $399.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.